| |
| | Bayer and SmithKline Beecham Launch Competitively-Priced... (Site not responding. Last check: 2007-10-23) |
 | | West Haven, CT/Philadelphia, PA February 18, 1998 Bayer Corporation Pharmaceutical Division and SmithKline Beecham (SB) announced today the launch of BAYCOL (cerivastatin sodium tablets), a new cholesterol-lowering agent of the statin class of drugs. |
 | | BAYCOL, an HMG-CoA reductase inhibitor, is indicated as an adjunct to diet for the reduction of elevated total and low-density lipoprotein cholesterol (LDL-C) levels in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson types IIa and IIb) when response to dietary restriction of saturated fat and cholesterol and other non-pharmacological measures alone have been inadequate. |
 | | SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures, and markets pharmaceuticals, vaccines, over-the-counter medicines, and health-related consumer products, and provides healthcare services including clinical-laboratory testing, disease management, and pharmaceutical-benefit management. |
| www.bayerus.com /new/1998/2.18.98.html (1174 words) |
|